Takeda Pharmaceutical (TAK) Share-based Compensation (2018 - 2026)
Takeda Pharmaceutical (TAK) posted quarterly Share-based Compensation of $114.1 million for Q2 2026, little changed year-over-year from $114.2 million in Q2 2025, and down 9.2% quarter-over-quarter from $125.7 million in Q1 2026.
Takeda Pharmaceutical (TAK) Share-based Compensation (2018 - 2026) Analysis & Trends
Takeda Pharmaceutical's Share-based Compensation history runs 9 years deep, the most recent figure standing at $114.1 million for Q2 2026.
- In Q2 2026, Share-based Compensation changed 0.11% year-over-year to $114.1 million; the TTM figure through Jun 2026 stood at $482.6 million (down 2.44% YoY), while the FY2026 annual figure was $483.5 million, up 1.07% from the prior year.
- Share-based Compensation for Q2 2026 stood at $114.1 million, down from $125.7 million in the prior quarter.
- The five-year high for Share-based Compensation was $144.5 million in Q3 2024, with the low at $95.0 million in Q2 2022.
- The 5-year median for Share-based Compensation is $116.2 million (2025), against an average of $117.3 million.
- The sharpest annual moves came in 2022 and 2024: Share-based Compensation rose 21.73% in 2022, then decreased 12.28% in 2024.
- Takeda Pharmaceutical's Share-based Compensation stood at $116.7 million in 2022, then advanced by 8.43% to $126.6 million in 2023, then decreased by 4.88% to $120.4 million in 2024, then decreased by 3.9% to $115.7 million in 2025, then decreased by 1.34% to $114.1 million in 2026.
- Business Quant data shows TAK's Share-based Compensation at $114.1 million in Q2 2026, $125.7 million in Q1 2026, and $115.7 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.85 Bn | 42.88 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.02 Bn | 39.37 Bn | 2.15 Bn | 40.00 Mn |
| 3 | Zoetis | 31.47 Bn | 29.79 Bn | 1.05 Bn | 26.00 Mn |
| 4 | Takeda Pharmaceutical | 28.59 Bn | 22.79 Bn | 5.10 Bn | 114.12 Mn |
| 5 | United Therapeutics | 22.20 Bn | 19.53 Bn | 683.80 Mn | 19.00 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | 30.40 Mn |
| 7 | Neurocrine Biosciences | 15.45 Bn | 15.06 Bn | 935.80 Mn | 65.00 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 7.00 Mn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | - |
| 10 | Alkermes | 8.07 Bn | 7.42 Bn | 397.90 Mn | 31.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 114.12 Mn |
| Jun 30, 2026 | 114.12 Mn |
| Mar 31, 2026 | 125.69 Mn |
| Mar 31, 2026 | 125.69 Mn |
| Dec 31, 2025 | 115.68 Mn |
| Dec 31, 2025 | 115.68 Mn |
| Sep 30, 2025 | 127.12 Mn |
| Sep 30, 2025 | 127.12 Mn |
| Jun 30, 2025 | 114.25 Mn |
| Jun 30, 2025 | 114.25 Mn |
| Mar 31, 2025 | 115.54 Mn |
| Mar 31, 2025 | 115.54 Mn |
| Dec 31, 2024 | 120.37 Mn |
| Dec 31, 2024 | 120.37 Mn |
| Sep 30, 2024 | 144.50 Mn |
| Sep 30, 2024 | 144.50 Mn |
| Jun 30, 2024 | 98.84 Mn |
| Jun 30, 2024 | 98.84 Mn |
| Mar 31, 2024 | 122.73 Mn |
| Mar 31, 2024 | 122.73 Mn |